Neurochemical Manipulation of Withdrawal-Induced Drinking

戒断性饮酒的神经化学调控

• 批准号: 7687530
• 负责人: DEBORAH A. FINN
• 金额: $ 27.72万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-15 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7687530
• 关键词: Agonist; Air; Alcohol consumption; Alcohols; Amygdaloid structure; Animals; Baclofen; Behavioral Model; Blood; Brain; Brain region; C57BL/6 Mouse; CRF receptor type 1; Cell Nucleus; Chronic; Complement 3a; Complement 3b; Complement 3c; Complement component C1s; Complex; Control Groups; Convulsions; Corticotropin-Releasing Hormone Receptors; Data; Dependence; Development; Environment; Ethanol; Ethanol dependence; Exposure to; FOS gene; Genetic; Glutamates; Injection of therapeutic agent; Intoxication; Laboratories; Lateral; Lead; Maps; Microinjections; Modeling; Modification; Mus; Naltrexone; Neuropeptides; Neurotransmitters; Opioid Receptor; Peptides; Phenotype; Physical Dependence; Procedures; Publishing; Research; Role; Self Administration; Site; Techniques; Withdrawal; Withdrawal Symptom; acamprosate; alcoholism therapy; base; drinking; indexing; insight; neuroadaptation; neurobiological mechanism; neurochemistry; phenylalanyl corticotropin-releasing factor; public health relevance; receptor; relating to nervous system; treatment strategy; urocortin; vapor

DESCRIPTION (provided by applicant): We have been using a combination of genetic and environmental manipulations to induce high ethanol intake in mice, defined as alcohol intake leading to a blood ethanol concentration (BEC) greater than 100 mg%. We determined that exposure to intermittent ethanol vapor and multiple withdrawal episodes (i.e., MW group) produced high ethanol consumption and withdrawal symptoms that were consistent with the development of physical dependence in these animals. This procedure has been termed "Withdrawal-Induced Drinking" (WID) and is thought to be one behavioral model of the increased alcohol consumption in dependent animals (also termed "dependence-induced" drinking). Preliminary data indicate that acamprosate (complex glutamatergic modulator), but not naltrexone (opioid receptor antagonist), significantly decreased the expression of WID. Subsequent studies determined that systemic administration of baclofen (GABAB receptor agonist), MPEP (mGluR5 antagonist), and NBI 27914 (CRF1 receptor antagonist) significantly decreased the expression of WID. Finally, intra amygdala administration of the CRF receptor antagonist D-Phe-CRF(12-41) also selectively decreased the high alcohol intake in the MW group without altering ethanol intake in the Control group. The present proposal will continue this line of inquiry with the WID model to determine the key neurotransmitters and neuropeptides that modulate the expression of WID and begin to discern neural sites that are important for the expression of WID. We hypothesize that neuroadaptations in the central nucleus of the amygdala (CeA) and lateral septum are important for the expression of WID. Aim 1 will pharmacologically manipulate the neurochemical environment of the lateral septum, whereas Aim 2 will manipulate the neurochemical environment of the CeA, to determine the neurotransmitters and neuropeptides that are important for the high alcohol intake and expression of WID in mice. Proposed studies will use a brain site- specific microinjection technique to manipulate the GABAergic, glutamatergic, and CRF peptide environment of the lateral septum and CeA. Microinjection of receptor agonists and antagonists will allow us to determine whether the MW and Control groups are differentially sensitive to these neurochemical manipulations of the CeA and lateral septum, and whether the manipulations are sufficient to modulate the expression of WID. Collectively, the proposed research will examine the neurobiological mechanisms underlying the high alcohol consumption WID phenotype. Not only will this information help in furthering our understanding of the mechanisms underlying dependence-induced drinking, but it also will aid in the development of new strategies for the treatment of alcoholism. PUBLIC HEALTH RELEVANCE The proposed research will examine the neurobiological mechanisms underlying high alcohol consumption in dependent animals. Studies will use a brain site-specific microinjection technique to determine the key neurotransmitters and neuropeptides that modulate the increased alcohol consumption in dependent animals and begin to discern neural sites that are important for this increased alcohol intake. Not only will this information help in furthering our understanding of the mechanisms underlying dependence-induced drinking, but it also will aid in the development of new strategies for the treatment of alcoholism.

描述（由申请人提供）：我们一直在使用遗传和环境操作的组合来诱导小鼠的高乙醇摄入，定义为导致血液乙醇浓度（BEC）大于100 mg%的酒精摄入。我们确定暴露于间歇性乙醇蒸汽和多次戒断发作（即，MW组）产生高乙醇消耗和戒断症状，这与这些动物中身体依赖性的发展一致。这个过程被称为“戒断诱导的饮酒”（WID），被认为是依赖性动物中酒精消耗增加的一种行为模型（也称为“依赖诱导的”饮酒）。初步数据表明，阿坎酸（复杂的多巴胺能调节剂），而不是纳洛酮（阿片受体拮抗剂），显着降低WID的表达。随后的研究确定，全身给予巴氯芬（GABAB受体激动剂）、MPEP（mGluR 5拮抗剂）和NBI 27914（CRF 1受体拮抗剂）显著降低了WID的表达。最后，杏仁核内施用CRF受体拮抗剂D-Phe-CRF（12-41）也选择性地减少MW组中的高酒精摄入，而不改变对照组中的酒精摄入。本建议将继续这一调查线与WID模型，以确定关键的神经递质和神经肽，调节WID的表达和开始辨别神经网站是重要的WID的表达。我们推测杏仁核中央核（CeA）和外侧隔的神经适应是重要的WID的表达。目的1将间接操纵外侧隔的神经化学环境，而目的2将操纵CeA的神经化学环境，以确定对小鼠高酒精摄入和WID表达重要的神经递质和神经肽。拟议的研究将使用脑部位特异性显微注射技术来操纵外侧隔和CeA的GABA能、多巴胺能和CRF肽环境。受体激动剂和拮抗剂的显微注射将使我们能够确定MW组和对照组是否对CeA和侧隔的这些神经化学操作具有差异敏感性，以及这些操作是否足以调节WID的表达。总的来说，拟议的研究将检查高酒精消费WID表型的神经生物学机制。这些信息不仅有助于我们进一步了解依赖性饮酒的潜在机制，而且还有助于开发治疗酒精中毒的新策略。公共卫生相关性拟议的研究将检查依赖动物高酒精消费的神经生物学机制。研究将使用脑部位特异性显微注射技术来确定调节依赖性动物酒精摄入量增加的关键神经递质和神经肽，并开始辨别对酒精摄入量增加重要的神经部位。这些信息不仅有助于我们进一步了解依赖性饮酒的潜在机制，而且还有助于开发治疗酒精中毒的新策略。